Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

33.70 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gsk Plc ADR

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
35 36 Next >
A Look Into GSK Inc's Price Over Earnings
Via Benzinga
GSK, Pfizer Lock Horns Over Patent Fight Related To Respiratory Syncytial Virus Vaccine
GSK Plc (NYSE: GSK) has sued Pfizer Inc (NYSE: PFE) in Delaware court, alleging that Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violates GSK's four patent rights in its RSV  
Via Benzinga
GSK's Jemperli Plus Chemo Combo Scores FDA Approval As First New Frontline Treatment For Certain Type Of Endometrial Cancer
The FDA approved GSK plc's (NYSE: GSK) Jemperli (dostarlimab) in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for primary advanced or recurrent endometrial cancer... 
Via Benzinga
Jemperli (dostarlimab-gxly) plus chemotherapy approved in the US as the first new frontline treatment option in decades for dMMR/MSI-H primary advanced or recurrent endometrial cancer
From GSK plc
Via Business Wire
Is GSK Stock Worth Buying Right Now?
GSK stock could be a bargain. 
Via The Motley Fool
A Look Into GSK's Debt
Via Benzinga
GSK's RSV Vaccine Scores Approval In UK For Older Adults
The U.K. 
Via Benzinga
(GSK) - Analyzing GSK's Short Interest
Via Benzinga
If You Can Only Buy One Dividend Stock, It Better Be One of These 7 Names
Here are seven of the best dividend stocks to consider immediately. Better, each of these stocks have strong, stable businesses. 
Via InvestorPlace
3 Millionaire-Maker Biotech Stocks to Buy Before the Window Closes
Here are three millionaire maker drug stocks from companies whose drugs could make truly staggering profits. 
Via InvestorPlace
GSK Says 'Excellent' Q2 Performance Boosted By Vaccine & HIV Drug Sales, Raises 2023 Outlook
GSK plc (NYSE: GSK) reported Q2 FY23 sales of £7.18 billion ($8.97 billion), up 4% Y/Y on t 
Via Benzinga
Pharma Giant GSK Beats Second-Quarter Goals On Growth In Vaccines, General Medicines
Pharmaceutical giant GSK beat expectations for the second quarter and raised its forecast for the full year. GSK stock rose on the news. 
Via Investor's Business Daily
Tesla's India Move, Adidas Receives Orders For Massive Unsold Yeezy Inventory, Spotify Raises Subscription Prices: Today's Top Stories
Wall Street Journal 
Via Benzinga
Better Artificial Intelligence Stock: GSK or Eli Lilly?
Which of these AI-powered drugmakers is the better buy right now? 
Via The Motley Fool
GSK-Pfizer Backed HIV-Focused Unit ViiV Healthcare's Cabotegravir Injected Drug, Tablets Secure European Backing For Approval
ViiV Healthcare received a positive opinion from the European Medicines Agen 
Via Benzinga
The 3 Most Undervalued Pharma Stocks to Buy Now: July 2023
Trading below a 15 forward price-to-earnings, these undervalued pharma stocks offer opportunities in an overbought market. 
Via InvestorPlace
Why Shares of Vir Biotechnology Are Plunging Thursday
The company had disappointing trial news for one of its lead therapies. 
Via The Motley Fool
Intercept Pharma Gets Double Upgrade: Analyst Says OCA Combo Therapy Can Extend PBC Business
HC Wainwright has upgraded Intercept Pharmaceuticals Inc (NASDAQ: ICPT) to Buy from Sell, with a price target of  
Via Benzinga
7 Stocks That AI Says Will Make You a Millionaire by 2025
These seven millionaire-maker stocks are changing hands at deeply undervalued levels. As their growth re-accelerates, so will your portfolio. 
Via InvestorPlace
3 Healthcare Stocks With Healthy Dividends
These pharmaceutical companies all combine relatively high dividends with safe payout ratios. 
Via The Motley Fool
GSK is first to ship influenza vaccine doses for the 2023-24 flu season in US
From GSK plc
Via Business Wire
3 No-Brainer Stocks to Buy With $50 Right Now
You don't need a treasure chest full of cash to begin building wealth on Wall Street. 
Via The Motley Fool
Why Are NanoViricides Shares Gaining Today
NanoViricides Inc (NYSE: NNVC) shares are trading higher after the company reported preclinical data from an antiviral clinical drug candidate for  
Via Benzinga
Meta's Threads Hits 100M Users In Five Days, Foxconn Pulls Out From $19.5B Semiconductor India JV, Novo Nordisk's Weight-Loss Medications Under European Investigation Over Suicidal Risks: Today's Top Stories
Benzinga 
Via Benzinga
From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs
Goldman Sachs compiled research suggesting the global pharmaceutical sector has approximately $700 billion available for M&A and investments. This significant financial reserve will be crucial as... 
Via Benzinga
Analyst Creates Bullish Pitch For WAVE Life Sciences, Says It Is 'Leader To Clinic In RNA Editing'
Raymond James has initiated coverage on WAVE Life Sciences Ltd (NASDAQ: WVE) with a price target of $9 and  
Via Benzinga
Teva's Strategic Evaluation: Israeli Pharma Company Mulls Divesting $2B Active Ingredients Unit
Teva Pharmaceutical Industries Ltd (NYSE: TEVA) is reportedly considering potential strategic options for its active pharmaceutical ingredients (API) unit, which could include a potential sale.  
Via Benzinga
Moderna Initiates Regulatory Application Process Seeking Approval For Its RSV Vaccine In Older Adults
Moderna Inc (NASDAQ: MRNA) provided an update on regulatory submissions for the mRNA-1345 vaccine to prevent RSV-associated lower respiratory tract disease (RSV-LRTD) and acute respiratory disease in  
Via Benzinga
Haleon Contemplates Sale of Non-Core Businesses, Including Nicotinell Brand: A Strategy Shift Towards Core Products
Haleon Plc (NYSE: HLN), a consumer health company, is reportedly considering divesting some smoking cessation products as part of a strategy to sell non-core businesses. 
Via Benzinga
First US Trial Over Zantac's Alleged Cancer-Causing Properties Set For November In California
The initial U.S. court trial concerning the antacid medication Zantac is slated to commence on November 13 in a state court in California, as stated by a lawyer representing the plaintiffs. 
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
35 36 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.